Two Indian Nationals Indicted in US Over Counterfeit Ozempic Smuggling Ring

Two Indian nationals have been indicted by a federal grand jury in Florida for allegedly importing and distributing counterfeit versions of the blockbuster diabetes and weight-loss medication Ozempic from China. According to Forbes, the United States Department of Justice announced the charges on September 29, stating that the illicit enterprise operated between July 2023 and April 2024.

According to U.S. Customs and Border Protection, u.S. Customs and Border Protection and FDA OCI have conducted joint interdiction blitzes at international shipping hubs, seizing hundreds of thousands of dollars in unapproved semaglutide products. According to U.S. Food and Drug Administration, for U.S. Food and Drug Administration, FDA counterfeit alerts detail that fraudulent Ozempic pens exhibit textual placement errors in EXP/LOT fields on labels and cartons, and fail manufacturer serial verification.

Swapnadip Roy and Vicky Ramancha were indicted on the charges. Furthermore, the scheme persisted even after the Food and Drug Administration seized certain shipments in December 2023 and published an advisory.

The case highlights international law enforcement efforts to crack down on illegal pharmaceutical smuggling networks targeting high-demand medical products. According to federal prosecutors, the defendants utilized deceptive packaging, inserts, and pen labels to pass off fake drugs as genuine medication to buyers across the United States.

Indictment and Extradition Details

Federal court documents identify the defendants as 33-year-old Swapnadip Roy and 37-year-old Vicky Ramancha. Roy was extradited from Italy and made his initial appearance in the U.S. District Court in Tampa, Florida, where he entered a plea of not guilty. Meanwhile, Ramancha remains at large, according to the Justice Department.

The indictment details that the two men orchestrated deals to supply discounted products to distributors in Florida. In July 2023, Ramancha allegedly executed an agreement with a company in Lakeland to supply counterfeit units at deeply discounted pricing, followed by a similar contract with a Sanford-based firm a month later for syringe supplies.

Continuation Despite Regulatory Warnings

Prosecutors asserted that the smuggling operation persisted even after domestic regulators intervened. The U.S. Food and Drug Administration seized shipments of the counterfeit supplies in December 2023 and issued a public safety warning regarding the fraudulent medications.

Court filings indicate that when a co-conspirator questioned whether the FDA warning would disrupt a pending order for 60,000 additional units, Ramancha allegedly directed them to ensure clients were not acting foolishly rather than halting the operation. Prosecutors also alleged that Roy employed violent threats in November 2023 to facilitate distribution channels within the country.

Charges and Maximum Penalties

The defendants face multiple federal counts, including conspiracy to commit smuggling and to defraud the United States, three counts of smuggling, and two counts of selling counterfeit drugs while holding them for commercial distribution.

If convicted on all counts, Roy and Ramancha face a combined maximum prison sentence of up to 71 years. Legal representatives for Roy did not immediately respond to requests for comment, while counsel for Ramancha was not immediately available.

Market Impact and Regulatory Concerns

The prosecution unfolds against a backdrop of soaring demand for GLP-1 receptor agonists used for weight management and diabetes management. Gallup polling published in July 2026 noted that 11 percent of U.S. adults reported taking GLP-1 medications, up significantly from 3 percent in 2024.

Assistant Attorney General A. Tysen Duva emphasized that counterfeit prescription drugs pose direct threats to public health and consumer safety, warning that federal authorities will continue pursuing networks attempting to exploit medical demand through fraudulent pharmaceutical imports.

According to CBS News, for Novo Nordisk, Testing of seized counterfeit pens revealed dangerous active ingredient substitutions including insulin, which induced severe hypoglycemic seizures in unwitting patients. According to U.S. Department of Justice, for U.S. Department of Justice Criminal Division, Trial Attorney Peter Leininger of the Health & Safety Unit and Assistant U.S. Attorney Ross Roberts are prosecuting the case, with DOJ's Office of International Affairs coordinating cross-border detention.